# Tanja Schirmeister

## List of Publications by Year in Descending Order

**Source:** https://exaly.com/author-pdf/4591690/tanja-schirmeister-publications-by-year.pdf
**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 177 papers | 4,612 citations | 35 h-index | 57 g-index |
| 196 ext. papers | 5,199 ext. citations | 5.3 avg, IF | 5.42 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 177 | A low-cost 3D-printable differential scanning fluorometer for protein and RNA melting experiments.. *HardwareX*, **2022**, 11, e00256 | 2.7 | 0 |
| 176 | Investigation of the influence of chirality and halogen atoms on the anticancer activity of enantiopure palladium(ii) complexes derived from chiral amino-alcohol Schiff bases and 2-picolylamine. *New Journal of Chemistry*, **2022**, 46, 6470-6483 | 3.6 | 1 |
| 175 | Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense.. *European Journal of Medicinal Chemistry*, **2022**, 236, 114328 | 6.8 | 0 |
| 174 | Chemical biology and medicinal chemistry of RNA methyltransferases.. *Nucleic Acids Research*, **2022** , | 20.1 | 2 |
| 173 | New peptidomimetic rhodesain inhibitors with improved selectivity towards human cathepsins. *European Journal of Medicinal Chemistry*, **2022**, 114460 | 6.8 | 0 |
| 172 | 2-Sulfonylpyrimidines as Privileged Warheads for the Development of Sortase A Inhibitors.. *Frontiers in Molecular Biosciences*, **2021**, 8, 804970 | 5.6 | 1 |
| 171 | Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening. *Journal of Chemical Information and Modeling*, **2021**, 61, 2062-2073 | 6.1 | 15 |
| 170 | Warhead Reactivity Limits the Speed of Inhibition of the Cysteine Protease Rhodesain. *ACS Chemical Biology*, **2021**, 16, 661-670 | 4.9 | 3 |
| 169 | Structural Determinants for the Mode of Action of Imidazopyridine DS2 at Containing Aminobutyric Acid Type A Receptors. *Journal of Medicinal Chemistry*, **2021**, 64, 4730-4743 | 8.3 | 5 |
| 168 | Synthesis, X-ray Structure Determination, and Comprehensive Photochemical Characterization of (Trifluoromethyl)diazirine-Containing TRPML1 Ligands. *Journal of Organic Chemistry*, **2021**, 86, 6169-6183 | 4.2 | 3 |
| 167 | Conformational Dynamics of the Dengue Virus Protease Revealed by Fluorescence Correlation and Single-Molecule FRET Studies. *Journal of Physical Chemistry B*, **2021**, 125, 6837-6846 | 3.4 | 4 |
| 166 | The discovery of novel antitrypanosomal 4-phenyl-6-(pyridin-3-yl)pyrimidines. *European Journal of Medicinal Chemistry*, **2021**, 209, 112871 | 6.8 | 1 |
| 165 | Similarities and Differences between Crystal and Enzyme Environmental Effects on the Electron Density of Drug Molecules. *Chemistry - A European Journal*, **2021**, 27, 3407-3419 | 4.8 | 6 |
| 164 | Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2. *ChemMedChem*, **2021**, 16, 340-354 | 3.7 | 17 |
| 163 | BANDT: BFactor Analysis for Drug Design and Structural Biology. *Molecular Informatics*, **2021**, 40, e2000184 | 3.4 | 4 |
| 162 | GNPS-guided discovery of xylacremolide C and D, evaluation of their putative biosynthetic origin and bioactivity studies of xylacremolide A and B. *RSC Advances*, **2021**, 11, 18748-18756 | 3.7 | 0 |
| 161 | Structure, interdomain dynamics, and pH-dependent autoactivation of pro-rhodesain, the main lysosomal cysteine protease from African trypanosomes. *Journal of Biological Chemistry*, **2021**, 296, 100565 | 5.4 | 3 |

| | | | |
|---|---|---|---|
| 160 | The Medicinal Chemistry of Zika Virus **2021**, 233-295 | | 1 |
| 159 | Applicability of a single-use bioreactor compared to a glass bioreactor for the fermentation of filamentous fungi and evaluation of the reproducibility of growth in pellet form. *Engineering in Life Sciences*, **2021**, 21, 324-339 | 3.4 | 0 |
| 158 | Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies. *Journal of Medicinal Chemistry*, **2021**, 64, 12322-12358 | 8.3 | 3 |
| 157 | SAR of novel benzothiazoles targeting an allosteric pocket of DENV and ZIKV NS2B/NS3 proteases. *Bioorganic and Medicinal Chemistry*, **2021**, 47, 116392 | 3.4 | 6 |
| 156 | Peptidyl Vinyl Ketone Irreversible Inhibitors of Rhodesain: Modifications of the P2 Fragment. *ChemMedChem*, **2020**, 15, 1552-1561 | 3.7 | 7 |
| 155 | Modular Solid-Phase Synthesis of Antiprotozoal Barnesin Derivatives. *Organic Letters*, **2020**, 22, 3744-3748 | 5.2 | 2 |
| 154 | Asymmetric Disulfanylbenzamides as Irreversible and Selective Inhibitors of Staphylococcus aureus Sortase A. *ChemMedChem*, **2020**, 15, 839-850 | 3.7 | 16 |
| 153 | Nostotrebin 6 Related Cyclopentenediones and δ-Lactones with Broad Activity Spectrum Isolated from the Cultivation Medium of the Cyanobacterium sp. CBT1153. *Journal of Natural Products*, **2020**, 83, 392-400 | 4.9 | 2 |
| 152 | Drug Synergism: Studies of Combination of RK-52 and Curcumin against Rhodesain of. *ACS Medicinal Chemistry Letters*, **2020**, 11, 806-810 | 4.3 | 3 |
| 151 | New Cysteine Protease Inhibitors: Electrophilic (Het)arenes and Unexpected Prodrug Identification for the Protease Rhodesain. *Molecules*, **2020**, 25, | 4.8 | 9 |
| 150 | Naphthoquinones as Covalent Reversible Inhibitors of Cysteine Proteases-Studies on Inhibition Mechanism and Kinetics. *Molecules*, **2020**, 25, | 4.8 | 14 |
| 149 | Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System. *Molecules*, **2020**, 25, | 4.8 | 4 |
| 148 | Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery. *Cells*, **2020**, 9, | 7.9 | 6 |
| 147 | Evaluation of curcumin irreversibility. *Natural Product Research*, **2020**, 34, 3159-3162 | 2.3 | 2 |
| 146 | Eliciting callus culture for production of hepatoprotective flavonoids and phenolics from (D. Don Endl). *Natural Product Research*, **2020**, 34, 3125-3129 | 2.3 | 4 |
| 145 | FINDUS: An Open-Source 3D Printable Liquid-Handling Workstation for Laboratory Automation in Life Sciences. *SLAS Technology*, **2020**, 25, 190-199 | 3 | 11 |
| 144 | Metabolomics analysis and biological investigation of three Malvaceae plants. *Phytochemical Analysis*, **2020**, 31, 204-214 | 3.4 | 15 |
| 143 | Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense. *ChemMedChem*, **2020**, 15, 995-1001 | 3.7 | 3 |

| | | | |
|---|---|---|---|
| 142 | Anticancer study of heterobimetallic platinum(II)-ruthenium(II) and platinum(II)-rhodium(III) complexes with bridging dithiooxamide ligand. *Journal of Organometallic Chemistry*, **2019**, 900, 120918 | 2.3 | 11 |
| 141 | Cis autocatalytic cleavage of glycine-linked Zika virus NS2B-NS3 protease constructs. *FEBS Letters*, **2019**, 593, 2204-2213 | 3.8 | 8 |
| 140 | Structure of the Human TRPML2 Ion Channel Extracytosolic/Lumenal Domain. *Structure*, **2019**, 27, 1246-1257.e5 | 3.5 | 10 |
| 139 | Synthesis and Pharmacological Evaluation of [C]4-Methoxy--[2-(thiophen-2-yl)imidazo[1,2-]pyridin-3-yl]benzamide as a Brain Penetrant PET Ligand Selective for the Subunit-Containing Aminobutyric Acid Type A Receptors. *ACS Omega*, **2019**, 4, 8846-8851 | 3.9 | 6 |
| 138 | Identification of a potential allosteric site of Golgi mannosidase II using computer-aided drug design. *PLoS ONE*, **2019**, 14, e0216132 | 3.7 | 4 |
| 137 | Promising trypanocidal heterocyclic compounds of natural origin and their synthetic analogs **2019**, 165-217 | | 1 |
| 136 | Synthesis, solution behaviour and potential anticancer activity of new trinuclear organometallic palladium(II) complex of {S}-1-phenylethyl dithiooxamide: Comparison with the trinuclear heterobimetallic platinum(II) analogue. *Polyhedron*, **2019**, 164, 195-201 | 2.7 | 7 |
| 135 | Drug combination studies of curcumin and genistein against rhodesain of. *Natural Product Research* , **2019**, 33, 3577-3581 | 2.3 | 7 |
| 134 | Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis. *Journal of Medicinal Chemistry*, **2019**, 62, 10617-10629 | 8.3 | 11 |
| 133 | Ruthenium(ii) and palladium(ii) homo- and heterobimetallic complexes: synthesis, crystal structures, theoretical calculations and biological studies. *Dalton Transactions*, **2019**, 48, 15869-15887 | 4.3 | 4 |
| 132 | Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases. *Journal of Medicinal Chemistry*, **2019**, 62, 11359-11382 | 8.3 | 35 |
| 131 | Structure-Function Evaluation of Imidazopyridine Derivatives Selective for Subunit-Containing Aminobutyric Acid Type A (GABA) Receptors. *Journal of Medicinal Chemistry*, **2018**, 61, 1951-1968 | 8.3 | 17 |
| 130 | Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8CTE inhibitors as potential therapeutics for leishmaniasis. *Chemical Biology and Drug Design*, **2018**, 92, 1585-1596 | 2.9 | 15 |
| 129 | Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 3350-3369 | 8.3 | 15 |
| 128 | 2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design. *Journal of Medicinal Chemistry*, **2018**, 61, 3370-3388 | 8.3 | 26 |
| 127 | Ensemble-based ADME-Tox profiling and virtual screening for the discovery of new inhibitors of the Leishmania mexicana cysteine protease CPB2.8CTE. *Chemical Biology and Drug Design*, **2018**, 91, 597-604 | 2.9 | 9 |
| 126 | New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8. *European Journal of Medicinal Chemistry*, **2018**, 156, 587-597 | 6.8 | 7 |
| 125 | Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 4624-4634 | 3.4 | 16 |

| | | | |
|---|---|---|---|
| 124 | Natural Product Repertoire of the Genus. *Marine Drugs*, **2018**, 17, | 6 | 9 |
| 123 | Approaching an experimental electron density model of the biologically active trans-epoxysuccinyl amide group□Substituent effects vs. crystal packing. *Journal of Physical Organic Chemistry*, **2017**, 30, e3683 | 2.1 | 4 |
| 122 | Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 2485-2497 | 8.3 | 82 |
| 121 | Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents. *BioMetals*, **2017**, 30, 313-320 | 3.4 | 18 |
| 120 | Inhibition of the Cysteine Protease Human Cathepsin L by Triazine Nitriles: Amide???Heteroarene □Stacking Interactions and Chalcogen Bonding in the S3 Pocket. *ChemMedChem*, **2017**, 12, 257-270 | 3.7 | 35 |
| 119 | Cytotoxicity of Endoperoxides from the Caribbean Sponge Plakortis halichondrioides towards Sensitive and Multidrug-Resistant Leukemia Cells: Acids vs. Esters Activity Evaluation. *Marine Drugs*, **2017**, 15, | 6 | 4 |
| 118 | Bistacrines as potential antitrypanosomal agents. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 4526-4531 | 3.4 | 4 |
| 117 | Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs). *Journal of Medicinal Chemistry*, **2017**, 60, 6911-6923 | 8.3 | 31 |
| 116 | Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 45-50 | 2.9 | 23 |
| 115 | Bistacrine derivatives as new potent antimalarials. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 3636-42 | 3.4 | 12 |
| 114 | Fluorine Scan of Inhibitors of the Cysteine Protease Human Cathepsin L: Dipolar and Quadrupolar Effects in the □Stacking of Fluorinated Phenyl Rings on Peptide Amide Bonds. *ChemMedChem*, **2016**, 11, 1042-7 | 3.7 | 28 |
| 113 | Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 3453-6 | 2.9 | 13 |
| 112 | Quantum Chemical-Based Protocol for the Rational Design of Covalent Inhibitors. *Journal of the American Chemical Society*, **2016**, 138, 8332-5 | 16.4 | 47 |
| 111 | Taspase1: a □misunderstood□protease with translational cancer relevance. *Oncogene*, **2016**, 35, 3351-64 | 9.2 | 17 |
| 110 | Targeting of the Leishmania mexicana cysteine protease CPB2.8□CTE by decorated fused benzo[b]thiophene scaffold. *RSC Advances*, **2016**, 6, 30628-30635 | 3.7 | 19 |
| 109 | Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2016**, 31, 1184-91 | 5.6 | 17 |
| 108 | Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 797-805 | 5.9 | 12 |
| 107 | Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. *European Journal of Medicinal Chemistry*, **2016**, 121, 578-591 | 6.8 | 18 |

| | | | |
|---|---|---|---|
| 106 | Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain. *ACS Medicinal Chemistry Letters*, **2016**, 7, 1073-1076 | 4.3 | 31 |
| 105 | Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: inhibition kinetics and docking studies. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 466-70 | 3.4 | 76 |
| 104 | Vinyl sulfone building blocks in covalently reversible reactions with thiols. *New Journal of Chemistry* , **2015**, 39, 5841-5853 | 3.6 | 14 |
| 103 | Anti-trypanosomal activities and structural chemical properties of selected compound classes. *Parasitology Research*, **2015**, 114, 501-12 | 2.4 | 6 |
| 102 | Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 7053-60 | 3.4 | 20 |
| 101 | Novel dengue virus NS2B/NS3 protease inhibitors. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1100-9 | 5.9 | 80 |
| 100 | Electrostatic complementarity in pseudoreceptor modeling based on drug molecule crystal structures: the case of loxistatin acid (E64c). *New Journal of Chemistry*, **2015**, 39, 1628-1633 | 3.6 | 10 |
| 99 | A hyaluronic acid–pentamidine bioconjugate as a macrophage mediated drug targeting delivery system for the treatment of leishmaniasis. *RSC Advances*, **2015**, 5, 95545-95550 | 3.7 | 15 |
| 98 | Dipeptidyl Enoates As Potent Rhodesain Inhibitors That Display a Dual Mode of Action. *ChemMedChem*, **2015**, 10, 1484-7 | 3.7 | 15 |
| 97 | Synthesis of C3/C1-Substituted Tetrahydroisoquinolines. *Molecules*, **2015**, 20, 14902-14 | 4.8 | 14 |
| 96 | Natural products as inhibitors of recombinant cathepsin L of Leishmania mexicana. *Experimental Parasitology*, **2015**, 156, 42-8 | 2.1 | 23 |
| 95 | Fly versus man: evolutionary impairment of nucleolar targeting affects the degradome of Drosophila Taspase1. *FASEB Journal*, **2015**, 29, 1973-85 | 0.9 | 8 |
| 94 | Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 83, 1-14 | 6.8 | 22 |
| 93 | Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. *Journal of Inorganic Biochemistry*, **2014**, 141, 79-82 | 4.2 | 22 |
| 92 | Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents. *ChemMedChem*, **2014**, 9, 1801-16 | 3.7 | 13 |
| 91 | Evidence for substrate binding-induced zwitterion formation in the catalytic Cys-His dyad of the SARS-CoV main protease. *Biochemistry*, **2014**, 53, 5930-46 | 3.2 | 59 |
| 90 | Biochemistry and medicinal chemistry of the dengue virus protease. *Chemical Reviews*, **2014**, 114, 11348-811 | 6.8 | 89 |
| 89 | Identification of a new series of amides as non-covalent proteasome inhibitors. *European Journal of Medicinal Chemistry*, **2014**, 76, 1-9 | 6.8 | 20 |

| | | | |
|---|---|---|---|
| 88 | Identification of plakortide E from the Caribbean sponge Plakortis halichondroides as a trypanocidal protease inhibitor using bioactivity-guided fractionation. *Marine Drugs*, **2014**, 12, 2614-22 | 6 | 15 |
| 87 | Cathepsin B in antigen-presenting cells controls mediators of the Th1 immune response during Leishmania major infection. *PLoS Neglected Tropical Diseases*, **2014**, 8, e3194 | 4.8 | 22 |
| 86 | Synthesis and biological evaluation of papain-family cathepsin L-like cysteine protease inhibitors containing a 1,4-benzodiazepine scaffold as antiprotozoal agents. *ChemMedChem*, **2014**, 9, 1817-25 | 3.7 | 18 |
| 85 | Protocol for rational design of covalently interacting inhibitors. *ChemPhysChem*, **2014**, 15, 3226-35 | 3.2 | 16 |
| 84 | Benchmark Study for the Cysteine-Histidine Proton Transfer Reaction in a Protein Environment: Gas Phase, COSMO, QM/MM Approaches. *Journal of Chemical Theory and Computation*, **2013**, 9, 1765-77 | 6.4 | 33 |
| 83 | Optimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin L. *ChemMedChem*, **2013**, 8, 967-75 | 3.7 | 40 |
| 82 | Development of peptidomimetic boronates as proteasome inhibitors. *European Journal of Medicinal Chemistry*, **2013**, 64, 23-34 | 6.8 | 31 |
| 81 | Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead. *ChemMedChem*, **2013**, 8, 2070-87 | 3.7 | 27 |
| 80 | Can Experimental Electron-Density Studies be Used as a Tool to Predict Biologically Relevant Properties of Low-Molecular Weight Enzyme Ligands?. *Zeitschrift Fur Anorganische Und Allgemeine Chemie*, **2013**, 639, 1905-1921 | 1.3 | 9 |
| 79 | Tuning and predicting biological affinity: aryl nitriles as cysteine protease inhibitors. *Organic and Biomolecular Chemistry*, **2012**, 10, 5764-8 | 3.9 | 42 |
| 78 | Antioxidant and anti-protease activities of diazepinomicin from the sponge-associated Micromonospora strain RV115. *Marine Drugs*, **2012**, 10, 2208-21 | 6 | 52 |
| 77 | Die Bedeutung ionischer Bindungsanteile in Schwefeldioxid Bindungsordnungen aus Rntgenbeugungsdaten. *Angewandte Chemie*, **2012**, 124, 6880-6884 | 3.6 | 20 |
| 76 | The significance of ionic bonding in sulfur dioxide: bond orders from X-ray diffraction data. *Angewandte Chemie - International Edition*, **2012**, 51, 6776-9 | 16.4 | 83 |
| 75 | Synthesis and molecular modeling studies of derivatives of a highly potent peptidomimetic vinyl ester as falcipain-2 inhibitors. *ChemMedChem*, **2012**, 7, 1594-600 | 3.7 | 23 |
| 74 | Identification of the protease inhibitor miraziridine A in the Red sea sponge Theonella swinhoei. *Pharmacognosy Research (discontinued)*, **2012**, 4, 63-6 | 0.7 | 8 |
| 73 | Reactivity differences between unsaturated carbonyls and hydrazones investigated by experimental and theoretical electron density and electron localizability analyses. *Journal of Physical Chemistry A*, **2011**, 115, 12715-32 | 2.8 | 21 |
| 72 | Challenging Problems in Charge Density Determination: Polar Bonds and Influence of the Environment. *Structure and Bonding*, **2011**, 47-97 | 0.9 | 14 |
| 71 | Peptidomimetic nitriles as selective inhibitors for the malarial cysteine protease falcipain-2. *MedChemComm*, **2011**, 2, 800 | 5 | 20 |

| | | | |
|---|---|---|---|
| 70 | New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities. *Marine Drugs*, **2011**, 9, 1682-97 | 6 | 20 |
| 69 | Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro. *Journal of Inorganic Biochemistry*, **2011**, 105, 1576-9 | 4.2 | 16 |
| 68 | Effect of electron-withdrawing substituents on the epoxide ring: an experimental and theoretical electron density analysis of a series of epoxide derivatives. *Journal of Organic Chemistry*, **2011**, 76, 1305-18 | 4.2 | 19 |
| 67 | Anti-protease and immunomodulatory activities of bacteria associated with Caribbean sponges. *Marine Biotechnology*, **2011**, 13, 883-92 | 3.4 | 30 |
| 66 | New cis-configured aziridine-2-carboxylates as aspartic acid protease inhibitors. *ChemMedChem*, **2011**, 6, 141-52 | 3.7 | 14 |
| 65 | Potent and selective inhibition of cysteine proteases from Plasmodium falciparum and Trypanosoma brucei. *ChemMedChem*, **2011**, 6, 273-8 | 3.7 | 28 |
| 64 | Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors. *ChemMedChem*, **2011**, 6, 1228-37 | 3.7 | 38 |
| 63 | Development of antitrypanosomal and antiplasmodial nonpeptidic cysteine protease inhibitors based on N-protected-guanidino-furan and -pyrrole building blocks. *ChemMedChem*, **2011**, 6, 1581-6 | 3.7 | 7 |
| 62 | Quantitative detection of C-deuterated drugs by CARS microscopy and Raman microspectroscopy. *Analyst, The*, **2011**, 136, 3686-93 | 5 | 35 |
| 61 | Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors. *European Journal of Medicinal Chemistry*, **2011**, 46, 2058-65 | 6.8 | 28 |
| 60 | Aziridine-2,3-dicarboxylate-based cysteine cathepsin inhibitors induce cell death in Leishmania major associated with accumulation of debris in autophagy-related lysosome-like vacuoles. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 5028-41 | 5.9 | 31 |
| 59 | Inducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 78-87 | 5.9 | 3 |
| 58 | Enzyme kinetics and hit validation in fluorimetric protease assays. *Current Topics in Medicinal Chemistry*, **2010**, 10, 368-82 | 3 | 28 |
| 57 | Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids. *Journal of Medicinal Chemistry*, **2010**, 53, 1951-63 | 8.3 | 43 |
| 56 | Mechanistic study of the reaction of thiol-containing enzymes with alpha,beta-unsaturated carbonyl substrates by computation and chemoassays. *ChemMedChem*, **2010**, 5, 869-80 | 3.7 | 26 |
| 55 | Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 4928-38 | 3.4 | 26 |
| 54 | Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 5541-3 | 2.9 | 46 |
| 53 | Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain. *European Journal of Medicinal Chemistry*, **2010**, 45, 3228-33 | 6.8 | 28 |

| | | | |
|---|---|---|---|
| 52 | Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6505-11 | 3.4 | 24 |
| 51 | Rational design of improved aziridine-based inhibitors of cysteine proteases. *Journal of Physical Chemistry B*, **2009**, 113, 5282-9 | 3.4 | 19 |
| 50 | Origin of the reactivity differences of substituted aziridines: CN vs CC bond breakages. *Journal of Organic Chemistry*, **2009**, 74, 5244-9 | 4.2 | 27 |
| 49 | On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences. *Journal of Medicinal Chemistry*, **2009**, 52, 5662-72 | 8.3 | 15 |
| 48 | Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 2157-60 | 8.3 | 66 |
| 47 | Transcriptome and functional analysis of the eukaryotic-type serine/threonine kinase PknB in Staphylococcus aureus. *Journal of Bacteriology*, **2009**, 191, 4056-69 | 3.5 | 83 |
| 46 | Synthesis and evaluation of non-peptidic cysteine protease inhibitors of P. falciparum derived from etacrynic acid. *Molecules*, **2008**, 14, 19-35 | 4.8 | 6 |
| 45 | Effect of protease inhibitors on exflagellation in Plasmodium falciparum. *Molecular and Biochemical Parasitology*, **2008**, 158, 208-12 | 1.9 | 23 |
| 44 | Atomistic insights into the inhibition of cysteine proteases: first QM/MM calculations clarifying the stereoselectivity of epoxide-based inhibitors. *Journal of Physical Chemistry B*, **2008**, 112, 11798-808 | 3.4 | 41 |
| 43 | A comparative study on the experimentally derived electron densities of three protease inhibitor model compounds. *Organic and Biomolecular Chemistry*, **2008**, 6, 2295-307 | 3.9 | 44 |
| 42 | Atomistic insights into the inhibition of cysteine proteases: first QM/MM calculations clarifying the regiospecificity and the inhibition potency of epoxide- and aziridine-based inhibitors. *Journal of Physical Chemistry B*, **2008**, 112, 5458-69 | 3.4 | 41 |
| 41 | Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors. *Journal of Medicinal Chemistry*, **2008**, 51, 988-96 | 8.3 | 170 |
| 40 | On the origin of the stabilization of the zwitterionic resting state of cysteine proteases: a theoretical study. *Journal of the American Chemical Society*, **2008**, 130, 8696-705 | 16.4 | 50 |
| 39 | Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 146-56 | 5.9 | 31 |
| 38 | Cis-Configured aziridines are new pseudo-irreversible dual-mode inhibitors of Candida albicans secreted aspartic protease 2. *ChemMedChem*, **2008**, 3, 302-15 | 3.7 | 17 |
| 37 | Nonpeptidic vinyl and allyl phosphonates as falcipain-2 inhibitors. *ChemMedChem*, **2008**, 3, 1030-3 | 3.7 | 41 |
| 36 | Electron-Density Determination of Electrophilic Building Blocks as Model Compounds for Protease Inhibitors. *European Journal of Organic Chemistry*, **2007**, 2007, 2759-2768 | 3.2 | 28 |
| 35 | The importance of the active site histidine for the activity of epoxide- or aziridine-based inhibitors of cysteine proteases. *ChemMedChem*, **2007**, 2, 120-8 | 3.7 | 37 |

| | | | |
|---|---|---|---|
| 34 | Screening of protease inhibitors as antiplasmodial agents. Part I: Aziridines and epoxides. *ChemMedChem*, **2007**, 2, 1214-24 | 3.7 | 39 |
| 33 | Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2164-72 | 5.9 | 24 |
| 32 | Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 2753-7 | 2.9 | 73 |
| 31 | Rational design of aziridine-containing cysteine protease inhibitors with improved potency: studies on inhibition mechanism. *ChemMedChem*, **2006**, 1, 1021-8 | 3.7 | 35 |
| 30 | Aziridide-based inhibitors of cathepsin L: synthesis, inhibition activity, and docking studies. *ChemMedChem*, **2006**, 1, 1126-41 | 3.7 | 53 |
| 29 | Inhibitors of cysteine proteases. *Current Topics in Medicinal Chemistry*, **2006**, 6, 331-53 | 3 | 74 |
| 28 | Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 2439-47 | 5.9 | 50 |
| 27 | A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. *Journal of Medicinal Chemistry*, **2005**, 48, 6832-42 | 8.3 | 49 |
| 26 | Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 5365-9 | 2.9 | 39 |
| 25 | Theoretical studies about the influence of different ring substituents on the nucleophilic ring opening of three-membered heterocycles and possible implications for the mechanisms of cysteine protease inhibitors. *Journal of Organic Chemistry*, **2005**, 70, 233-7 | 4.2 | 53 |
| 24 | Development and validation of a separation method for the diastereomers and enantiomers of aziridine-type protease inhibitors. *Electrophoresis*, **2005**, 26, 2313-9 | 3.6 | 12 |
| 23 | Comparison of the separation of aziridine isomers applying heptakis(2,3-di-O-methyl-6-sulfato)beta-CD and heptakis(2,3-di-O-acetyl-6-sulfato)beta-CD in aqueous and nonaqueous systems. *Electrophoresis*, **2005**, 26, 3897-903 | 3.6 | 5 |
| 22 | Blocking effect of a biotinylated protease inhibitor on the egress of Plasmodium falciparum merozoites from infected red blood cells. *Biological Chemistry*, **2005**, 386, 499-502 | 4.5 | 19 |
| 21 | New non-peptidic inhibitors of papain derived from etacrynic acid. *Medicinal Chemistry*, **2005**, 1, 361-70 | 1.8 | 6 |
| 20 | Synthesis and antiplasmodial activity of a cysteine protease-inhibiting biotinylated aziridine-2,3-dicarboxylate. *Biological Chemistry*, **2004**, 385, 435-8 | 4.5 | 25 |
| 19 | Thiirancarboxamides as inhibitors of papain. *Archiv Der Pharmazie*, **2004**, 337, 90-5 | 4.3 | 1 |
| 18 | Conformation and Hydrogen Bonding Properties of an Aziridinyl Peptide: X-ray Structure Analysis, Raman Spectroscopy and Theoretical Investigations. *Journal of Physical Chemistry A*, **2004**, 108, 11398-11408 | 2.8 | 12 |
| 17 | Model Calculations about the Influence of Protic Environments on the Alkylation Step of Epoxide, Aziridine, and Thiirane Based Cysteine Protease Inhibitors. *Journal of Physical Chemistry A*, **2004**, 108, 7691-7701 | 2.8 | 51 |

| | | | |
|---|---|---|---|
| 16 | Cysteine protease inhibitors containing small rings. *Mini-Reviews in Medicinal Chemistry*, **2003**, 3, 585-96 | 3.2 | 37 |
| 15 | Non-peptidic inhibitors of cysteine proteases. *Mini-Reviews in Medicinal Chemistry*, **2003**, 3, 361-73 | 3.2 | 24 |
| 14 | An improved synthesis of aziridine-2,3-dicarboxylates via azido alcohols□pimerization studies. *Tetrahedron: Asymmetry*, **2003**, 14, 3301-3312 | | 34 |
| 13 | beta-Lactam derivatives as enzyme inhibitors: 1-peptidyl derivatives of 4-phenylazetidin-2-one as inhibitors of elastase and papain. *Archiv Der Pharmazie*, **2000**, 333, 243-53 | 4.3 | 25 |
| 12 | (S)-Thiirancarboxylic acid as a reactive building block for a new class of cysteine protease inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 2647-51 | 2.9 | 14 |
| 11 | Aziridinyl peptides as inhibitors of cysteine proteases: effect of a free carboxylic acid function on inhibition. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 1281-91 | 3.4 | 48 |
| 10 | Synthesis of peptides with aziridine-2,3-dicarboxylic acid as an □amino acid equivalent building block **1999**, 634-636 | | |
| 9 | Inhibition of cysteine proteases by peptides containing aziridine-2,3-dicarboxylic acid building blocks. *Biopolymers*, **1999**, 51, 87-97 | 2.2 | 13 |
| 8 | New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid. *Journal of Medicinal Chemistry*, **1999**, 42, 560-72 | 8.3 | 59 |
| 7 | Metallionen als Coinhibitoren von Serin-Proteasen: ein neuer Ansatz bei der Suche nach hochaffinen und spezifischen Liganden. *Angewandte Chemie*, **1998**, 110, 1930-1932 | 3.6 | |
| 6 | Metal Ions as Co-Inhibitors of Serine Proteases: A New Approach in the Search for Specific High-Affinity Ligands. *Angewandte Chemie - International Edition*, **1998**, 37, 1830-1832 | 16.4 | 2 |
| 5 | Cysteine Proteases and Their Inhibitors. *Chemical Reviews*, **1997**, 97, 133-172 | 68.1 | 626 |
| 4 | Aziridine-2,2-dicarboxylates: Synthesis, Reactions, and Photochromism. *Liebigs Annalen*, **1997**, 1997, 1895-1899 | | 18 |
| 3 | Aziridine-2,3-dicarboxylic Acid Derivatives as Inhibitors of Papain. *Archiv Der Pharmazie*, **1996**, 329, 239-244 | 4.3 | 23 |
| 2 | Enzyme-catalyzed hydrolyses of E/Z-diastereotopic and E/Z-diastereomeric esters. Effect on selectivity by reaction media. *Journal of Organic Chemistry*, **1993**, 58, 4819-4822 | 4.2 | 23 |
| 1 | E/Z Diastereoselective Enzymatic Hydrolysis of Esters and Diesters. *Angewandte Chemie International Edition in English*, **1993**, 32, 572-574 | | 3 |